In addition, we confirmed that HE treatment reduced by 2.4− and 2.5-fold (p < 0.01), respectively, the immunoreactivity of GFAP and Iba1 in anterior horn of the spinal cord compared to those of the Tg group (Figure 6D). The gene discussed is GFAP; the disease is hereditary elliptocytosis.